1. Home
  2. BBY vs RPRX Comparison

BBY vs RPRX Comparison

Compare BBY & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBY
  • RPRX
  • Stock Information
  • Founded
  • BBY 1966
  • RPRX 1996
  • Country
  • BBY United States
  • RPRX United States
  • Employees
  • BBY N/A
  • RPRX N/A
  • Industry
  • BBY Consumer Electronics/Video Chains
  • RPRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BBY Consumer Discretionary
  • RPRX Health Care
  • Exchange
  • BBY Nasdaq
  • RPRX Nasdaq
  • Market Cap
  • BBY 15.6B
  • RPRX 16.2B
  • IPO Year
  • BBY N/A
  • RPRX 2020
  • Fundamental
  • Price
  • BBY $78.90
  • RPRX $40.88
  • Analyst Decision
  • BBY Buy
  • RPRX Strong Buy
  • Analyst Count
  • BBY 19
  • RPRX 3
  • Target Price
  • BBY $81.76
  • RPRX $46.00
  • AVG Volume (30 Days)
  • BBY 3.5M
  • RPRX 2.9M
  • Earning Date
  • BBY 11-25-2025
  • RPRX 11-05-2025
  • Dividend Yield
  • BBY 4.80%
  • RPRX 2.16%
  • EPS Growth
  • BBY N/A
  • RPRX N/A
  • EPS
  • BBY 3.63
  • RPRX 1.60
  • Revenue
  • BBY $41,598,000,000.00
  • RPRX $2,349,553,000.00
  • Revenue This Year
  • BBY $1.64
  • RPRX $36.16
  • Revenue Next Year
  • BBY $1.33
  • RPRX $2.04
  • P/E Ratio
  • BBY $21.82
  • RPRX $25.42
  • Revenue Growth
  • BBY N/A
  • RPRX 3.69
  • 52 Week Low
  • BBY $54.99
  • RPRX $24.05
  • 52 Week High
  • BBY $95.49
  • RPRX $41.24
  • Technical
  • Relative Strength Index (RSI)
  • BBY 47.75
  • RPRX 75.93
  • Support Level
  • BBY $81.60
  • RPRX $36.03
  • Resistance Level
  • BBY $82.60
  • RPRX $37.40
  • Average True Range (ATR)
  • BBY 2.08
  • RPRX 1.11
  • MACD
  • BBY -0.52
  • RPRX 0.38
  • Stochastic Oscillator
  • BBY 9.51
  • RPRX 93.15

About BBY Best Buy Co. Inc.

With over $41 billion in consolidated 2024 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8% share of the North American market and around 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: